IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
IDEXX LABORATORIES INC /DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$555.80−4.56 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $44.08B
- P/E (TTM)
- 39.1
- Dividend yield
- –
IDEXX LABORATORIES INC /DE revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAG segment revenue | $1.12B | $1.05B | $998.47M | $1.01B | $1.02B | $919.84M | $870.47M | $891.99M | $922.30M | $889.29M | $821.27M | $837.16M | 91.9% | +9.4% |
| Water segment revenue | $58.56M | $50.27M | $50.53M | $54.30M | $51.00M | $45.32M | $45.15M | $50.16M | $46.73M | $43.07M | $41.79M | $44.45M | 4.8% | +14.8% |
| LPD | $35.18M | $32.48M | $37.49M | $33.94M | $31.76M | $28.60M | $34.56M | $28.99M | $30.31M | $28.21M | $32.79M | $29.75M | 2.9% | +10.8% |
| Other segment revenue | – | – | – | – | – | – | – | $4.40M | $4.25M | $3.53M | $5.76M | $4.17M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAG segment revenue | – | – | – | – | – | – | – | $277.08M | $241.55M | $279.70M | $222.12M | $253.36M | – |
| Water segment revenue | – | – | – | – | – | – | – | $23.61M | $20.50M | $19.43M | $17.22M | $20.33M | – |
| LPD | – | – | – | – | – | – | – | $889.00K | $1.50M | $866.00K | $4.31M | $2.41M | – |
| Other segment revenue | – | – | – | – | – | – | – | $2.31M | $248.00K | -$1.03M | $1.65M | -$808.00K | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $718.63M | $666.12M | $652.44M | $656.16M | $657.56M | $573.05M | $559.87M | $567.99M | $577.27M | $543.05M | $521.83M | $521.49M | 59.1% | +9.3% |
| Service revenue | $497.96M | $474.70M | $438.14M | $449.08M | $451.90M | $425.38M | $394.42M | $407.56M | $426.31M | $421.05M | $379.78M | $394.04M | 40.9% | +10.2% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $772.97M | $725.23M | $675.02M | $705.04M | $717.87M | $654.86M | $603.96M | $638.06M | $660.15M | $631.01M | $576.36M | $603.05M | 63.5% | +7.7% |
| Europe, the Middle East and Africa | $265.53M | $257.05M | $254.37M | $245.06M | $233.27M | $204.55M | $207.61M | $198.61M | $200.69M | $199.83M | $183.66M | $177.85M | 21.8% | +13.8% |
| Asia Pacific | $101.50M | $94.38M | $94.17M | $90.72M | $89.30M | $81.73M | $83.31M | $80.97M | $80.44M | $76.30M | $82.38M | $77.67M | 8.3% | +13.7% |
| Canada | $50.79M | $40.94M | $41.96M | $41.38M | $46.69M | $37.30M | $38.26M | $36.93M | $40.99M | $36.71M | $36.90M | $35.61M | 4.2% | +8.8% |
| Latin America & Caribbean | $25.81M | $23.22M | – | $23.04M | $22.33M | $19.99M | – | $20.98M | $21.32M | $20.24M | – | $21.35M | 2.1% | +15.6% |
From the segment and revenue-disaggregation notes of Idexx Laboratories's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.